Research Portal

Professor Dyfrig Hughes

Athro mewn Ffarmacoeconomeg / Cyfarwyddwr Ymchwil

Affiliations

Links

ORCID: 0000-0001-8247-7459
1 - 50 out of 459Page size: 50
  1. 2000
  2. Published

    The influence of non-compliance on the effectiveness and cost-effectiveness of drug therapies

    Hughes, D., Hughes, D. A., Bagust, A., Haycox, A. & Walley, T., 1 Jan 2000, In: Value in Health. 3, 5, p. 373

    Research output: Contribution to journal › Article › peer-review

  3. Published

    Pragmatic trials - design features and implications for clinical decision making

    Hughes, D., Urdahl, H., Hughes, D. A. & Freemantle, N., 1 Aug 2000.

    Research output: Contribution to conference › Paper

  4. Published

    The influence of non-compliance on the effectiveness and cost-effectiveness of drug therapies

    Hughes, D., Hughes, D. A., Bagust, A., Haycox, A. & Walley, T., 1 Nov 2000.

    Research output: Contribution to conference › Paper

  5. 2001
  6. Published

    A review of economic models for second-line chemotherapy in the management of advanced, metastatic breast cancer.

    Hughes, D. & Hughes, D. A., 1 Jan 2001, 2001 ed. Unknown.

    Research output: Book/Report › Commissioned report

  7. Published

    Accounting for non-compliance in pharmacoeconomic evaluations.

    Hughes, D., Hughes, D. A., Bagust, A., Haycox, A. & Walley, T., 1 Jan 2001, In: Pharmacoeconomics. 19, 12, p. 1185-1197

    Research output: Contribution to journal › Article › peer-review

  8. Published

    Economic evaluations during early (Phase II) drug development: A role for clinical trial simulations.

    Hughes, D., Hughes, D. A. & Walley, T., 1 Jan 2001, In: Pharmacoeconomics. 19, 11, p. 1069-1077

    Research output: Contribution to journal › Article › peer-review

  9. Published

    Pharmacokinetic-Pharmacodynamic modelling of Lapdap (CPG-DDS) combination.

    Hughes, D., Hughes, D. A., Watkins, B. & Winstanley, P., 1 Jan 2001, 2001 ed. Unknown.

    Research output: Book/Report › Commissioned report

  10. Published

    The influence of non-compliance on the effectiveness and cost-effectiveness of drug therapies.

    Hughes, D. & Hughes, D. A., 1 Jan 2001, 2001 ed. Unknown.

    Research output: Book/Report › Commissioned report

  11. Published

    Impact of non-compliance on the cost-effectiveness of statin therapy

    Hughes, D., Hughes, D. A. & Bagust, A., 1 Sept 2001, In: Value in Health. 4, 6, p. 489

    Research output: Contribution to journal › Article › peer-review

  12. Published

    Pharmacometric analysis of duration of drug action: implications for improved forgiveness to medication non-compliance

    Hughes, D., Hughes, D. A. & Walley, T., 1 Sept 2001.

    Research output: Contribution to conference › Paper

  13. Published

    Patient compliance and pharmacoeconomics

    Hughes, D. & Hughes, D. A., 1 Oct 2001.

    Research output: Contribution to conference › Paper

  14. Published

    The impact of non-compliance on the cost-effectiveness of pharmaceuticals: A review of the literature.

    Hughes, D., Hughes, D. A., Bagust, A., Haycox, A. & Walley, T., 1 Oct 2001, In: Health Economics. 10, 7, p. 601-615

    Research output: Contribution to journal › Article › peer-review

  15. Published

    Impact of non-compliance on the clinical and cost-effectiveness of statins

    Hughes, D. & Hughes, D. A., 1 Nov 2001.

    Research output: Contribution to conference › Paper

  16. 2002
  17. Published

    Impact of non-compliance on the therapeutic coverage of oxybutynin – comparison of once- and twice-daily oral formulations.

    Hughes, D. & Hughes, D. A., 1 Jan 2002, 2002 ed. Unknown.

    Research output: Book/Report › Commissioned report

  18. Published

    Impact of non-compliance on the therapeutic coverage of risperidone – comparison of long acting injectible with oral formulations.

    Hughes, D. & Hughes, D. A., 1 Jan 2002, 2002 ed. Unknown.

    Research output: Book/Report › Commissioned report

  19. Published

    From efficacy to cost-effectiveness: accounting for non-compliance in pharmacoeconomics

    Hughes, D. & Hughes, D. A., 1 May 2002.

    Research output: Contribution to conference › Paper

  20. Published

    Economic impact of poor compliance with pharmaceuticals.

    Hughes, D. & Hughes, D. A., 1 Aug 2002, In: Expert Review of Pharmacoeconomics and Outcomes Research. 2, 4, p. 327-335

    Research output: Contribution to journal › Article › peer-review

  21. Published

    Accurate and practical dosing of African populations using a height, weight and age model designed for lapdap

    Hughes, D., Hughes, D. A. & Bagust, A., 1 Nov 2002.

    Research output: Contribution to conference › Paper

  22. Published

    Economic evaluation during early (phase II) trials

    Hughes, D. & Hughes, D. A., 1 Nov 2002.

    Research output: Contribution to conference › Paper

  23. Published

    Impact of non-compliance on the cost-effectiveness of pharmaceuticals

    Hughes, D. & Hughes, D. A., 1 Nov 2002.

    Research output: Contribution to conference › Paper

  24. Published

    Patient compliance and pharmacoeconomics

    Hughes, D. & Hughes, D. A., 1 Nov 2002.

    Research output: Contribution to conference › Paper

  25. Published

    The population pharmacokinetics of lapdap

    Hughes, D., Ward, S., Simpson, J., Aarons, L., Szwandt, S. & Hughes, D. A., 1 Nov 2002.

    Research output: Contribution to conference › Paper

  26. 2003
  27. Published

    Abacavir hypersensitivity: Is pre-prescription genotyping cost-effective?

    Hughes, D. & Hughes, D. A., 1 May 2003.

    Research output: Contribution to conference › Paper

  28. Published

    Abacavir hypersensitivity: Is pre-prescription genotyping cost-effective?

    Hughes, D. & Hughes, D. A., 1 Jun 2003.

    Research output: Contribution to conference › Paper

  29. Published

    Predicting "real world" effectiveness by integrating adherence with pharmacodynamic modelling.

    Hughes, D., Hughes, D. A. & Walley, T., 1 Jul 2003, In: Clinical Pharmacology and Therapeutics. 74, 1, p. 1-8

    Research output: Contribution to journal › Article › peer-review

  30. Published

    Abacavir hypersensitivity: Is pre-prescription genotyping cost-effective?

    Hughes, D., Hughes, D. A. & Pirmohamed, M., 1 Sept 2003.

    Research output: Contribution to conference › Paper

  31. Published

    Modelling changes in first line antimalarial therapy

    Hughes, D. & Hughes, D. A., 1 Sept 2003.

    Research output: Contribution to conference › Paper

  32. Published

    Abacavir hypersensitivity: Is pre-prescription genotyping cost-effective?

    Hughes, D., Hughes, D. A. & Pirmohamed, M., 1 Nov 2003.

    Research output: Contribution to conference › Paper

  33. Published

    Abacavir hypersensitivity: Is pre-prescription genotyping cost-effective?

    Hughes, D., Hughes, D. A. & Pirmohamed, M., 1 Nov 2003, In: Value in Health. 6, 6, p. 749

    Research output: Contribution to journal › Article › peer-review

  34. Published

    Cost-utility analysis of on demand rabeprazole and esomeprazole for symptomatic gastro oesophageal reflux disease

    Hughes, D., Hughes, D. A. & Dubois, D., 1 Nov 2003, In: Value in Health. 6, 6, p. 613

    Research output: Contribution to journal › Article › peer-review

  35. Published

    Cost-utility analysis of on-demand rabeprazole and esomeprazole for non-erosive reflux disease

    Hughes, D. & Hughes, D. A., 1 Nov 2003.

    Research output: Contribution to conference › Paper

  36. Published

    Cost-utility analysis of on-demand rabeprazole and esomeprazole for non-erosive reflux disease

    Hughes, D. & Hughes, D. A., 1 Nov 2003.

    Research output: Contribution to conference › Paper

  37. Published

    Use of PK-PD modelling to predict the impact of non-compliance

    Hughes, D. & Hughes, D. A., 1 Nov 2003.

    Research output: Contribution to conference › Paper

  38. Published

    Drug compliance and pharmaceconomics

    Hughes, D. & Hughes, D. A., 1 Dec 2003.

    Research output: Contribution to conference › Paper

  39. 2004
  40. Published

    Approaches to pharmacoeconomic analysis

    Hughes, D., Hughes, D. A., Walley, T. (Editor), Haycox, A. (Editor), Boland, A. (Editor) & Breckenridge, A. (Editor), 1 Jan 2004, Pharmacoeconomics. 2004 ed. Adis International, p. 101-126

    Research output: Chapter in Book/Report/Conference proceeding › Chapter

  41. Published

    Clinical Pharmacology: Special safety considerations in drug development and pharmacovigilance.

    Hughes, D., Atuah, K. N., Hughes, D. A. & Pirmohamed, M., 1 Jan 2004, In: Drug Safety. 27, 8, p. 535-554

    Research output: Contribution to journal › Article › peer-review

  42. Published

    Cost-effectiveness analysis of extended-release formulations of oxybutynin and tolterodine for the management of urge incontinence.

    Hughes, D., Hughes, D. A. & Dubois, D., 1 Jan 2004, In: Pharmacoeconomics. 22, 16, p. 1047-1059

    Research output: Contribution to journal › Article › peer-review

  43. Published

    Internationalisation of cost-effectiveness model for on-demand use of proton pump inhibitors - Belgium.

    Hughes, D. & Hughes, D. A., 1 Jan 2004, 2004 ed. Unknown.

    Research output: Book/Report › Commissioned report

  44. Published

    Modelling in health economics

    Hughes, D., Hughes, D. A., Walley, T. (Editor), Haycox, A. (Editor), Boland, A. (Editor) & Breckenridge, A. (Editor), 1 Jan 2004, Pharmacoeconomics. 2004 ed. Adis International, p. 141-154

    Research output: Chapter in Book/Report/Conference proceeding › Chapter

  45. Published

    The future challenges

    Hughes, D., Hughes, D. A., Walley, T. (Editor), Haycox, A. (Editor), Boland, A. (Editor) & Breckenridge, A. (Editor), 1 Jan 2004, Pharmacoeconomics. 2004 ed. Adis International, p. 167-174

    Research output: Chapter in Book/Report/Conference proceeding › Chapter

  46. Published

    Pharmacoeconomics in Wales: functions of the all Wales medicines strategy group

    Hughes, D. & Hughes, D. A., 1 Apr 2004.

    Research output: Contribution to conference › Paper

  47. Published

    Pharmacoeconomics of pharmacogenetic testing: azathioprine

    Hughes, D., McAllister, R. & Hughes, D. A., 1 Apr 2004.

    Research output: Contribution to conference › Paper

  48. Published

    Patient compliance and persistence with prescribed medication: Measurement and health economic impact

    Hughes, D., Koncz, T., Hughes, D. A., Cleemput, I. & Annemans, L., 1 May 2004.

    Research output: Contribution to conference › Paper

  49. Published

    Cost-effectiveness analysis of HLA B*5701 genotyping in preventing abacavir hypersensitivity

    Hughes, D., Hughes, D. A., Vilar, F. J., Ward, C. C., Alfirevic, A., Park, B. K. & Pirmohamed, M., 1 Jun 2004, In: Pharmacogenetics. 14, 6, p. 335-342

    Research output: Contribution to journal › Article › peer-review

  50. Published

    Introduction to pharmaeconomics

    Hughes, D. & Hughes, D. A., 1 Jul 2004.

    Research output: Contribution to conference › Paper

  51. Published

    Pharmacoeconomic models that incorporate non-compliance

    Hughes, D. & Hughes, D. A., 1 Jul 2004.

    Research output: Contribution to conference › Paper

  52. Published

    Pharmacoeconomics appraisals by the all Wales medicines strategy group

    Hughes, D. & Hughes, D. A., 1 Jul 2004.

    Research output: Contribution to conference › Paper

  53. Published

    The difference between effectiveness and efficacy of antimalarial drugs in Kenya.

    Hughes, D., Amin, A. A., Hughes, D. A., Marsh, V., Abuya, T. O., Kokwaro, G. O., Winstanley, P. A., Ochala, S. A. & Snow, R. W., 1 Sept 2004, In: Tropical Medicine and International Health. 9, 9, p. 967-974

    Research output: Contribution to journal › Article › peer-review

  54. Published
  55. Published

    A single centre open phase IV study to evaluate the safety and tolerability of chlorproguanil-dapsone when dosed by defined height bands

    Hughes, D., Makanga, M., Winstanley, P. & Hughes, D. A., 1 Nov 2004.

    Research output: Contribution to conference › Paper

Previous 1 2 3 4 5 6 7 8 ...10 Next